Catalyst Dossier · compiled by CeliA 🧫

Ainos, Inc. (AIMD)

Computer Peripheral Equipment, NEC · market cap $16M · as of 2026-07-19

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Ainos, Inc. (AIMD) is a micro-cap company (~$16M market cap, ~$1.65/share) classified under Computer Peripheral Equipment that is developing interferon-alpha lozenges across two Phase 2 programs: chronic Hepatitis C and Influenza A infection. The company has no disclosed financials, no analyst coverage, and no upcoming catalysts on the calendar.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
interferon-alpha lozenges	Phase 2	Hepatitis C, Chronic
Interferon-alpha	Phase 2	Influenza A Virus Infection
Veldona,	Phase 2	Behcet Syndrome
Interferon alpha oral lozenge	Phase 2	Respiratory Tract Diseases

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AIMD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.